PROPHYLACTIC USE OF 15(S)15 METHYL PGF_2α , BY INTRAMUSCULAR ROUTE - A CONTROLLED CLINICAL TRIAL

Area of Science:

• Obstetrics and Gynecology
• Pharmacology
• Reproductive Medicine

Background:

• Postpartum hemorrhage (PPH) remains a leading cause of maternal mortality worldwide.
• Effective prophylactic measures are crucial for managing the third stage of labor and preventing excessive blood loss.
• Oxytocic agents play a vital role in uterine contraction and PPH prevention.

Purpose of the Study:

• To compare the efficacy and safety of 15(S)15 methyl prostaglandin F2α (Prostin 15M) with ergometrine and a control group for preventing postpartum bleeding.
• To evaluate the impact of these interventions on the duration of the third stage of labor and blood loss.

Main Methods:

• A multicenter study involving 441 patients undergoing normal vaginal delivery.
• Intramuscular injection of 125 µg 15(S)15 methyl PGF2α (Prostin 15M) or ergometrine administered prophylactically.
• A control group received no oxytocic intervention.
• Measurements included duration of the third stage of labor and estimated blood loss.

Main Results:

• Prostin 15M significantly shortened the third stage of labor to 3.5 minutes, compared to 6.1 minutes for ergometrine and 7.6 minutes for controls.
• Prostin 15M resulted in less blood loss (95.2 ml) compared to ergometrine (154.0 ml) and controls (233.2 ml).
• Prostin 15M demonstrated superior efficacy over ergometrine in controlling postpartum blood loss.

Conclusions:

• 15(S)15 methyl prostaglandin F2α (Prostin 15M) is a safe and effective prophylactic agent for controlling postpartum bleeding.
• Prostin 15M offers advantages over ergometrine in reducing blood loss and shortening the third stage of labor.
• Prostin 15M represents a valuable therapeutic option in obstetric practice for PPH prevention.